|
US20080281041A1
(en)
*
|
1999-06-07 |
2008-11-13 |
Rozema David B |
Reversibly Masked Polymers
|
|
US9228186B2
(en)
|
2002-11-14 |
2016-01-05 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
|
US9879266B2
(en)
|
2002-11-14 |
2018-01-30 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
|
KR101141544B1
(ko)
|
2009-03-13 |
2012-05-03 |
한국과학기술원 |
에스아이알엔에이 다중 접합체 및 이의 제조방법
|
|
EP2406379A4
(en)
*
|
2009-03-13 |
2012-09-26 |
Egen Inc |
COMPOSITIONS AND METHODS FOR RELEASING BIOLOGICALLY ACTIVE RNA
|
|
DK2539451T3
(da)
*
|
2010-02-24 |
2016-04-04 |
Arrowhead Res Corp |
Sammensætninger til målrettet tilførsel af siRNA
|
|
US10913767B2
(en)
*
|
2010-04-22 |
2021-02-09 |
Alnylam Pharmaceuticals, Inc. |
Oligonucleotides comprising acyclic and abasic nucleosides and analogs
|
|
WO2012019168A2
(en)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
RU2013120302A
(ru)
|
2010-10-01 |
2014-11-20 |
Модерна Терапьютикс, Инк. |
Сконструированные нуклеиновые кислоты и способы их применения
|
|
EP2652134B1
(en)
|
2010-12-17 |
2017-03-01 |
Arrowhead Pharmaceuticals, Inc. |
Galactose cluster-pharmacokinetic modulator targeting moiety for sirna
|
|
US8501930B2
(en)
|
2010-12-17 |
2013-08-06 |
Arrowhead Madison Inc. |
Peptide-based in vivo siRNA delivery system
|
|
ES2605990T3
(es)
|
2010-12-29 |
2017-03-17 |
F. Hoffmann-La Roche Ag |
Conjugados de molécula pequeña para la administración intracelular de ácidos nucleicos
|
|
EP2691101A2
(en)
|
2011-03-31 |
2014-02-05 |
Moderna Therapeutics, Inc. |
Delivery and formulation of engineered nucleic acids
|
|
US9481661B2
(en)
|
2011-06-17 |
2016-11-01 |
Arrowhead Madison, Inc. |
Disubstituted maleic anhydrides with altered kinetics of ring closure
|
|
EP2807216A4
(en)
*
|
2011-08-26 |
2015-10-28 |
Arrowhead Res Corp |
POLY (VINYLESTER) POLYMERS FOR IN VIVO NUCLEIC ACID RELIEF
|
|
WO2013032829A1
(en)
|
2011-08-26 |
2013-03-07 |
Arrowhead Research Corporation |
Poly(vinyl ester) polymers for in vivo nucleic acid delivery
|
|
EP3453761A1
(en)
|
2011-08-29 |
2019-03-13 |
Ionis Pharmaceuticals, Inc. |
Oligomer-conjugate complexes and their use
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
RU2648950C2
(ru)
|
2011-10-03 |
2018-04-02 |
Модерна Терапьютикс, Инк. |
Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
|
|
CN104114572A
(zh)
|
2011-12-16 |
2014-10-22 |
现代治疗公司 |
经修饰的核苷、核苷酸和核酸组合物
|
|
CA2860228A1
(en)
*
|
2011-12-23 |
2013-06-27 |
Egen, Inc. |
Compositions and methods for the delivery of biologically active rnas
|
|
WO2013102878A2
(en)
|
2012-01-05 |
2013-07-11 |
Department Of Biotechnology (Dbt) |
Fat1 gene in cancer and inflammation
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
US9254311B2
(en)
|
2012-04-02 |
2016-02-09 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins
|
|
AU2013243948A1
(en)
|
2012-04-02 |
2014-10-30 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins associated with human disease
|
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
|
US9133461B2
(en)
|
2012-04-10 |
2015-09-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the ALAS1 gene
|
|
EP2838544A4
(en)
*
|
2012-04-18 |
2015-10-14 |
Arrowhead Res Corp |
POLY (ACRYLATE) POLYMERS FOR IN VIVO NUCLEIC ACID ADMINISTRATION
|
|
JP2015515530A
(ja)
*
|
2012-04-18 |
2015-05-28 |
アローヘッド リサーチ コーポレイション |
インビボ核酸送達のためのポリ（アクリラート）ポリマー
|
|
US9127274B2
(en)
*
|
2012-04-26 |
2015-09-08 |
Alnylam Pharmaceuticals, Inc. |
Serpinc1 iRNA compositions and methods of use thereof
|
|
AR090906A1
(es)
*
|
2012-05-02 |
2014-12-17 |
Merck Sharp & Dohme |
Conjugados que contienen tetragalnac y procedimientos para la administracion de oligonucleotidos
|
|
AR090905A1
(es)
*
|
2012-05-02 |
2014-12-17 |
Merck Sharp & Dohme |
Conjugados que contienen tetragalnac y peptidos y procedimientos para la administracion de oligonucleotidos, composicion farmaceutica
|
|
US10323279B2
(en)
*
|
2012-08-14 |
2019-06-18 |
10X Genomics, Inc. |
Methods and systems for processing polynucleotides
|
|
CA3216609C
(en)
|
2012-08-14 |
2024-05-14 |
10X Genomics, Inc. |
Microcapsule compositions and methods
|
|
US9801953B2
(en)
|
2012-10-15 |
2017-10-31 |
Emory University |
Nanoparticles carrying nucleic acid cassettes for expressing RNA
|
|
US10077443B2
(en)
|
2012-11-15 |
2018-09-18 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotide conjugates
|
|
WO2014081507A1
(en)
|
2012-11-26 |
2014-05-30 |
Moderna Therapeutics, Inc. |
Terminally modified rna
|
|
US9896688B2
(en)
*
|
2013-02-22 |
2018-02-20 |
Sirna Therapeutics, Inc. |
Short interfering nucleic acid (siNA) molecules containing a 2′ internucleoside linkage
|
|
SG10201706960TA
(en)
|
2013-02-28 |
2017-10-30 |
Arrowhead Res Corp |
Organic compositions to treat epas1-related diseases
|
|
EP2971010B1
(en)
|
2013-03-14 |
2020-06-10 |
ModernaTX, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
|
CN105164261B
(zh)
|
2013-05-01 |
2022-03-18 |
莱古路斯治疗法股份有限公司 |
用于增强的细胞摄取的化合物和方法
|
|
DK2991656T3
(da)
|
2013-05-01 |
2020-03-23 |
Ionis Pharmaceuticals Inc |
Sammensætninger og fremgangsmåder til modulering af apolipoprotein c-iii-ekspression
|
|
SG11201508925WA
(en)
|
2013-05-01 |
2015-11-27 |
Regulus Therapeutics Inc |
Microrna compounds and methods for modulating mir-122
|
|
WO2015021092A1
(en)
|
2013-08-07 |
2015-02-12 |
Arrowhead Research Corporation |
Polyconjugates for delivery of rnai triggers to tumor cells in vivo
|
|
US10023626B2
(en)
|
2013-09-30 |
2018-07-17 |
Modernatx, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
JP2016538829A
(ja)
|
2013-10-03 |
2016-12-15 |
モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
低密度リポタンパク質受容体をコードするポリヌクレオチド
|
|
TWI768330B
(zh)
|
2013-10-04 |
2022-06-21 |
美國西奈山伊坎醫學院 |
抑制alas1基因表現的組合物及方法
|
|
US9994846B2
(en)
|
2013-10-25 |
2018-06-12 |
Regulus Therapeutics Inc. |
MicroRNA compounds and methods for modulating miR-21 activity
|
|
KR20160083876A
(ko)
*
|
2013-11-14 |
2016-07-12 |
로슈 이노베이션 센터 코펜하겐 에이/에스 |
ApoB 안티센스 접합체 화합물
|
|
DK3137476T3
(da)
|
2014-04-28 |
2019-11-18 |
Ionis Pharmaceuticals Inc |
Linker-modificerede oligomerforbindelser
|
|
EP3862362A3
(en)
|
2014-05-01 |
2021-10-27 |
Ionis Pharmaceuticals, Inc. |
Conjugates of modified antisense oligonucleotides and their use for modulating pkk expression
|
|
PT3137605T
(pt)
|
2014-05-01 |
2020-12-18 |
Ionis Pharmaceuticals Inc |
Composições e métodos para modulação da expressão de angiopoietina de tipo 3
|
|
SG11201608502TA
(en)
|
2014-05-01 |
2016-11-29 |
Ionis Pharmaceuticals Inc |
Compositions and methods for modulating complement factor b expression
|
|
CN110903337A
(zh)
|
2014-05-01 |
2020-03-24 |
Ionis制药公司 |
用于调节生长激素受体表达的组合物和方法
|
|
KR102589295B1
(ko)
|
2014-05-14 |
2023-10-13 |
타르그이뮨 테라퓨틱스 아게 |
개선된 폴리에틸렌이민 폴리에틸렌글리콜 벡터
|
|
US10570169B2
(en)
|
2014-05-22 |
2020-02-25 |
Ionis Pharmaceuticals, Inc. |
Conjugated antisense compounds and their use
|
|
WO2015188194A1
(en)
*
|
2014-06-06 |
2015-12-10 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for enhanced intestinal absorption of conjugated oligomeric compounds
|
|
TW201620526A
(zh)
|
2014-06-17 |
2016-06-16 |
愛羅海德研究公司 |
用於抑制α－１抗胰蛋白酶基因表現之組合物及方法
|
|
TW201613949A
(en)
|
2014-08-07 |
2016-04-16 |
Regulus Therapeutics Inc |
Targeting microRNAs for metabolic disorders
|
|
BR112017004056A2
(pt)
|
2014-09-12 |
2017-12-05 |
Biogen Ma Inc |
composições e métodos para detecção da proteína smn em um indivíduo e tratamento de um indivíduo
|
|
TWI864340B
(zh)
*
|
2014-10-10 |
2024-12-01 |
美商艾爾妮蘭製藥公司 |
用於抑制hao1(羥酸氧化酶1(乙醇酸鹽氧化酶))基因表現的組合物及方法
|
|
WO2016055601A1
(en)
*
|
2014-10-10 |
2016-04-14 |
F. Hoffmann-La Roche Ag |
Galnac phosphoramidites, nucleic acid conjugates thereof and their use
|
|
AU2015330670B2
(en)
*
|
2014-10-10 |
2022-01-06 |
Novo Nordisk Health Care Ag |
Therapeutic inhibition of lactate dehydrogenase and agents therefor
|
|
WO2016061487A1
(en)
*
|
2014-10-17 |
2016-04-21 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
|
|
EP3221445B1
(en)
|
2014-11-20 |
2021-07-14 |
The Regents of The University of California |
Compositions and methods related to hematologic recovery
|
|
WO2016138132A1
(en)
*
|
2015-02-25 |
2016-09-01 |
The Trustees Of Columbia University In The City Of New York |
Dipeptidyl peptidase-iv(dpp4) inhibitors, methods and compositions for suppressing adipose tissue inflammation
|
|
JP2018509913A
(ja)
*
|
2015-03-17 |
2018-04-12 |
アローヘッド ファーマシューティカルズ インコーポレイテッド |
第ｘｉｉ因子の遺伝子発現を阻害するための組成物と方法
|
|
HK1252852A1
(zh)
|
2015-05-29 |
2019-06-06 |
Arrowhead Pharmaceuticals, Inc. |
阻止HIF2α基因表达的组合物及方法
|
|
IL316159A
(en)
|
2015-06-15 |
2024-12-01 |
Mpeg La Llc |
Defined Oligonucleotide Multimers and Methods for Manufacture Thereof
|
|
CA3012607A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Crispr enzymes and systems
|
|
US9790490B2
(en)
|
2015-06-18 |
2017-10-17 |
The Broad Institute Inc. |
CRISPR enzymes and systems
|
|
CA2991894A1
(en)
|
2015-07-10 |
2017-01-19 |
Ionis Pharmaceuticals, Inc. |
Modulators of diacyglycerol acyltransferase 2 (dgat2)
|
|
CA2982825C
(en)
*
|
2015-08-06 |
2023-10-17 |
F. Hoffmann-La Roche Ag |
Processes for the preparation of galnac acid derivatives
|
|
KR20180038465A
(ko)
|
2015-08-07 |
2018-04-16 |
애로우헤드 파마슈티컬스 인코포레이티드 |
Ｂ형 간염 바이러스 감염에 대한 ｒｎａｉ 치료법
|
|
JP6877414B2
(ja)
|
2015-09-24 |
2021-05-26 |
アイオニス・ファーマシューティカルズ・インコーポレイテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． |
Ｋｒａｓ発現のモジュレーター
|
|
JOP20160211B1
(ar)
|
2015-10-01 |
2021-08-17 |
Arrowhead Pharmaceuticals Inc |
تراكيب وأساليب لتثبيط تعبير جيني للـ lpa
|
|
US20190046555A1
(en)
|
2015-11-06 |
2019-02-14 |
Ionis Pharmaceuticals, Inc. |
Conjugated antisense compounds for use in therapy
|
|
AU2016349625B2
(en)
|
2015-11-06 |
2022-07-07 |
Ionis Pharmaceuticals, Inc. |
Modulating apolipoprotein (a) expression
|
|
MX378999B
(es)
|
2015-11-16 |
2025-03-10 |
Hoffmann La Roche |
Fosforamidita de agrupacion de n-acetilgalactosamina (galnac).
|
|
EP4454637A3
(en)
|
2015-11-16 |
2025-01-08 |
Olix Pharmaceuticals, Inc. |
Treatment of age-related macular degeneration using rna complexes that target myd88 or tlr3
|
|
FI3386518T3
(fi)
|
2015-12-07 |
2025-09-25 |
Genzyme Corp |
Menetelmiä ja koostumuksia serpinc1:een liittyvän häiriön hoitamiseksi
|
|
WO2017106657A1
(en)
|
2015-12-18 |
2017-06-22 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
|
KR102825946B1
(ko)
|
2016-02-02 |
2025-06-27 |
올릭스 주식회사 |
IL4Rα, TRPA1, 또는 F2RL1을 표적화하는 RNA 복합체를 사용한 아토피 피부염 및 천식의 치료
|
|
KR102515329B1
(ko)
*
|
2016-03-07 |
2023-03-29 |
애로우헤드 파마슈티컬스 인코포레이티드 |
치료용 화합물을 위한 표적화 리간드
|
|
US10407469B2
(en)
|
2016-04-01 |
2019-09-10 |
Northwestern University |
Programmable polypeptide and nucleic acid nanoparticles
|
|
SG10202008301UA
(en)
*
|
2016-04-11 |
2020-10-29 |
Arbutus Biopharma Corp |
Targeted nucleic acid conjugate compositions
|
|
EP3442983A1
(en)
|
2016-04-14 |
2019-02-20 |
H. Hoffnabb-La Roche Ag |
TRITYL-MONO-Ga1NAc COMPOUNDS AND THEIR USE
|
|
EP3445853A1
(en)
|
2016-04-19 |
2019-02-27 |
The Broad Institute, Inc. |
Cpf1 complexes with reduced indel activity
|
|
CN110382692A
(zh)
|
2016-04-19 |
2019-10-25 |
博德研究所 |
新型crispr酶以及系统
|
|
US10973774B2
(en)
|
2016-04-26 |
2021-04-13 |
Viaqua Therapeutics Ltd. |
Compositions and methods for treating viral infections in shrimps
|
|
WO2017214112A1
(en)
|
2016-06-06 |
2017-12-14 |
Arrowhead Pharmaceuticals, Inc. |
5'-cyclo-phosphonate modified nucleotides
|
|
ES2935658T3
(es)
|
2016-07-15 |
2023-03-09 |
Ionis Pharmaceuticals Inc |
Compuestos y métodos para la modulación de SMN2
|
|
WO2018017814A1
(en)
|
2016-07-20 |
2018-01-25 |
President And Fellows Of Harvard College |
Peptidoglycan glycosyltransferase inhibitors of sed proteins for treating bacterial infections
|
|
JOP20190015A1
(ar)
|
2016-08-04 |
2019-02-04 |
Arrowhead Pharmaceuticals Inc |
عوامل (ار ان ايه آي) لعدوى فيروس الالتهاب الكبدي الوبائي ب
|
|
MX2018009853A
(es)
*
|
2016-09-02 |
2018-11-09 |
Arrowhead Pharmaceuticals Inc |
Ligandos de direccion.
|
|
WO2018053142A2
(en)
|
2016-09-14 |
2018-03-22 |
President And Fellows Of Harvard College |
Methods and compositions for modulating erythropoiesis
|
|
EP3522898A4
(en)
|
2016-10-06 |
2020-05-27 |
Ionis Pharmaceuticals, Inc. |
METHOD FOR CONJUGATING OLIGOMERIC COMPOUNDS
|
|
WO2018112033A1
(en)
|
2016-12-13 |
2018-06-21 |
President And Fellows Of Harvard College |
Methods and compositions for targeting tumor-infiltrating tregs
|
|
WO2018112364A1
(en)
|
2016-12-16 |
2018-06-21 |
Evelo Biosciences, Inc. |
Combination therapies for treating melanoma
|
|
WO2018112360A1
(en)
|
2016-12-16 |
2018-06-21 |
Evelo Biosciences, Inc. |
Combination therapies for treating cancer
|
|
WO2018112365A2
(en)
|
2016-12-16 |
2018-06-21 |
Evelo Biosciences, Inc. |
Methods of treating colorectal cancer and melanoma using parabacteroides goldsteinii
|
|
US20190314427A1
(en)
|
2016-12-16 |
2019-10-17 |
Evelo Biosciences, Inc. |
Methods of treating cancer using parabacteroides
|
|
BR112019014282A2
(pt)
|
2017-01-10 |
2020-03-03 |
Arrowhead Pharmaceuticals, Inc. |
Agentes de rnai de antitripsina (aat) alfa-1, composições incluindo agentes de rnai de aat, e métodos de uso
|
|
WO2018136617A2
(en)
|
2017-01-18 |
2018-07-26 |
Evelo Biosciences, Inc. |
Methods of treating cancer
|
|
WO2018136598A1
(en)
|
2017-01-18 |
2018-07-26 |
Evelo Biosciences, Inc. |
Methods of treating cancer
|
|
AU2018213379A1
(en)
|
2017-01-30 |
2019-07-18 |
Arrowhead Pharmaceuticals Inc. |
Compositions and methods for inhibition of factor XII gene expression
|
|
EP3576752A4
(en)
|
2017-02-06 |
2020-12-16 |
Mpeg La, LLC |
MULTIMERIC OLIGONUCLEOTIDES WITH REDUCED RENAL CLEARANCE
|
|
JOP20190215A1
(ar)
*
|
2017-03-24 |
2019-09-19 |
Ionis Pharmaceuticals Inc |
مُعدّلات التعبير الوراثي عن pcsk9
|
|
WO2019193144A1
(en)
|
2018-04-05 |
2019-10-10 |
Silence Therapeutics Gmbh |
siRNAs WITH VINYLPHOSPHONATE AT THE 5' END OF THE ANTISENSE STRAND
|
|
WO2018191278A2
(en)
|
2017-04-11 |
2018-10-18 |
Arbutus Biopharma Corporation |
Targeted compositions
|
|
WO2018215049A1
(en)
|
2017-05-23 |
2018-11-29 |
F. Hoffmann-La Roche Ag |
Process for galnac oligonucleotide conjugates
|
|
TN2019000308A1
(en)
|
2017-07-06 |
2021-05-07 |
Arrowhead Pharmaceuticals Inc |
RNAi AGENTS FOR INHIBITING EXPRESSION OF ALPHA-ENaC AND METHODS OF USE
|
|
CA3069451A1
(en)
|
2017-07-13 |
2019-01-17 |
Alnylam Pharmaceuticals, Inc. |
Methods for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
|
|
US11241461B2
(en)
|
2017-08-29 |
2022-02-08 |
Evelo Biosciences, Inc. |
Treating cancer using a blautia strain
|
|
US10597657B2
(en)
|
2017-09-11 |
2020-03-24 |
Arrowhead Pharmaceuticals, Inc. |
RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)
|
|
MX2020001912A
(es)
|
2017-09-14 |
2020-03-24 |
Arrowhead Pharmaceuticals Inc |
Agentes de iarn y composiciones para inhibir la expresion de la angiopoyetina tipo 3 (angptl3) y metodos de uso.
|
|
HRP20231063T1
(hr)
|
2017-10-13 |
2023-12-22 |
Novo Nordisk Health Care Ag |
Postupci i pripravci namijenjeni inhibiranju eksprimiranja ldha
|
|
US11492624B2
(en)
|
2017-10-17 |
2022-11-08 |
Arrowheads Pharmaceuticals, Inc. |
RNAi agents and compositions for inhibiting expression of Asialoglycoprotein receptor 1
|
|
WO2019105435A1
(zh)
|
2017-12-01 |
2019-06-06 |
苏州瑞博生物技术有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
CN110945130B
(zh)
|
2017-12-01 |
2024-04-09 |
苏州瑞博生物技术股份有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
WO2019105437A1
(zh)
|
2017-12-01 |
2019-06-06 |
苏州瑞博生物技术有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
JP7365052B2
(ja)
|
2017-12-01 |
2023-10-19 |
スーチョウ リボ ライフ サイエンス カンパニー、リミテッド |
核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用
|
|
CA3083968C
(en)
|
2017-12-01 |
2024-04-23 |
Suzhou Ribo Life Science Co., Ltd. |
Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method thereof and use thereof
|
|
EA202091513A1
(ru)
|
2017-12-19 |
2020-09-09 |
Янссен Сайенсиз Айрлэнд Анлимитед Компани |
Вакцины против вируса гепатита b (hbv) и их применение
|
|
EP3732185B1
(en)
|
2017-12-29 |
2025-02-26 |
Suzhou Ribo Life Science Co., Ltd. |
Conjugates and preparation and use thereof
|
|
BR112020014425A2
(pt)
|
2018-01-15 |
2020-12-29 |
Ionis Pharmaceuticals, Inc. |
Moduladores de expressão de dnm2
|
|
AU2019213004B2
(en)
*
|
2018-01-29 |
2024-03-07 |
F. Hoffmann-La Roche Ag |
Process for the preparation of GalNAc oligonucleotide conjugates
|
|
AU2019218987B2
(en)
|
2018-02-12 |
2025-04-24 |
Ionis Pharmaceuticals, Inc. |
Modified compounds and uses thereof
|
|
WO2019169160A1
(en)
|
2018-02-28 |
2019-09-06 |
Evelo Biosciences, Inc. |
Compositions and methods for treating cancer using ruminococcus gnavus
|
|
WO2019169143A1
(en)
|
2018-02-28 |
2019-09-06 |
Evelo Biosciences, Inc. |
Compositions and methods for treating cancer using turicibacter sanguinis
|
|
WO2019169138A1
(en)
|
2018-02-28 |
2019-09-06 |
Evelo Biosciences, Inc. |
Compositions and methods for treating cancer using paraclostridium benzoelyticum
|
|
WO2019169168A1
(en)
|
2018-02-28 |
2019-09-06 |
Evelo Biosciences, Inc. |
Compositions and methods for treating cancer using agathobaculum
|
|
WO2019178057A1
(en)
|
2018-03-12 |
2019-09-19 |
Evelo Biosciences, Inc. |
Methods of treating cancer using burkholderia
|
|
WO2019217459A1
(en)
|
2018-05-07 |
2019-11-14 |
Alnylam Pharmaceuticals, Inc. |
Extrahepatic delivery
|
|
EP3790972A1
(en)
|
2018-05-08 |
2021-03-17 |
Regulus Therapeutics Inc. |
Galnac conjugated modified oligonucleotide as mir-122 inhibitor having hcv antiviral activity with reduced hyperbilirubinemia side-effect
|
|
JP7438135B2
(ja)
|
2018-05-09 |
2024-02-26 |
アイオーニス ファーマシューティカルズ， インコーポレーテッド |
Ｆｘｉの発現を低下させるための化合物及び方法
|
|
EP3823725A4
(en)
|
2018-07-17 |
2023-05-10 |
Aronora, Inc. |
METHODS FOR SAFELY REDUCING THROMBOPOIETIN
|
|
TW202019441A
(zh)
|
2018-07-20 |
2020-06-01 |
美商雷格勒斯治療公司 |
用於經口遞送寡核苷酸之方法
|
|
US20210292768A1
(en)
|
2018-08-08 |
2021-09-23 |
Arcturus Therapeutics, Inc. |
Compositions and agents against nonalcoholic steatohepatitis
|
|
US11918600B2
(en)
|
2018-08-21 |
2024-03-05 |
Suzhou Ribo Life Science Co., Ltd. |
Nucleic acid, pharmaceutical composition and conjugate containing nucleic acid, and use thereof
|
|
US11273137B2
(en)
|
2018-09-04 |
2022-03-15 |
Board Of Trustees Of Michigan State University |
Methods and compositions to prevent and treat disorders associated with mutations in the ODC1 gene
|
|
MX2021003077A
(es)
|
2018-09-19 |
2021-05-27 |
Arrowhead Pharmaceuticals Inc |
Agentes de arni para inhibir la expresion de 17beta-hsd tipo 13 (hsd17b13), composiciones de dichos agentes, y metodos de uso.
|
|
TWI856973B
(zh)
|
2018-09-19 |
2024-10-01 |
美商Ionis製藥公司 |
Pnpla3表現之調節劑
|
|
EP3862024A4
(en)
|
2018-09-30 |
2022-08-17 |
Suzhou Ribo Life Science Co., Ltd. |
SIRNA CONJUGATE, METHOD FOR ITS PRODUCTION AND ITS USE
|
|
EP3899024A4
(en)
|
2018-12-21 |
2023-05-31 |
Ionis Pharmaceuticals, Inc. |
Modulators of hsd17b13 expression
|
|
US12496347B2
(en)
|
2018-12-28 |
2025-12-16 |
Suzhou Ribo Life Science Co., Ltd. |
Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof
|
|
CN112423795A
(zh)
*
|
2018-12-28 |
2021-02-26 |
苏州瑞博生物技术股份有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
SG11202105577TA
(en)
|
2019-01-09 |
2021-06-29 |
Arrowhead Pharmaceuticals Inc |
Rnai agents for inhibiting expression of hif-2 alpha (epas1), compositions thereof, and methods of use
|
|
SG11202108395SA
(en)
|
2019-02-07 |
2021-08-30 |
Arrowhead Pharmaceuticals Inc |
Rnai agents for hepatitis b virus infection
|
|
CN114040799A
(zh)
|
2019-03-12 |
2022-02-11 |
哈佛大学校长及研究员协会 |
治疗癌症的方法和组合物
|
|
MA55720A
(fr)
|
2019-04-18 |
2022-02-23 |
Janssen Pharmaceuticals Inc |
Polythérapie pour le traitement d'une infection par le virus de l'hépatite b
|
|
US20200332297A1
(en)
|
2019-04-18 |
2020-10-22 |
Janssen Pharmaceuticals, Inc. |
Combination therapy for treating hepatitis b virus infection
|
|
US11510939B1
(en)
|
2019-04-19 |
2022-11-29 |
Apellis Pharmaceuticals, Inc. |
RNAs for complement inhibition
|
|
JP7610268B2
(ja)
|
2019-05-22 |
2025-01-08 |
スーチョウ リボ ライフ サイエンス カンパニー、リミテッド |
核酸、薬物組成物及び複合体ならびに調製方法と使用
|
|
WO2020233680A1
(zh)
|
2019-05-22 |
2020-11-26 |
苏州瑞博生物技术股份有限公司 |
核酸、药物组合物与缀合物及制备方法和用途
|
|
AU2020280438B2
(en)
|
2019-05-22 |
2025-03-06 |
Suzhou Ribo Life Science Co., Ltd. |
Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
|
|
EP3978609A4
(en)
|
2019-05-24 |
2024-02-07 |
Suzhou Ribo Life Science Co., Ltd. |
Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
|
|
MX2021015003A
(es)
|
2019-06-06 |
2022-01-24 |
Arrowhead Pharmaceuticals Inc |
Metodos para el tratamiento de la deficiencia de alfa-1 antitripsina (aatd).
|
|
US20220226269A1
(en)
|
2019-06-12 |
2022-07-21 |
President And Fellows Of Harvard College |
Methods and compositions for modulation of an interspecies gut bacterial pathway for levodopa metabolism
|
|
CA3143679A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and hbv-targeting rnai
|
|
KR20220042116A
(ko)
|
2019-06-18 |
2022-04-04 |
얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 |
B형 간염 바이러스(HBV) 백신 및 HBV-타케팅 RNAi의 조합
|
|
CN110218728A
(zh)
*
|
2019-06-28 |
2019-09-10 |
厦门甘宝利生物医药有限公司 |
一种新化合物及其应用
|
|
AU2020319911A1
(en)
*
|
2019-07-30 |
2022-02-24 |
Mpeg La, L.L.C. |
Subcutaneous delivery of multimeric oligonucleotides with enhanced bioactivity
|
|
WO2021022110A1
(en)
|
2019-08-01 |
2021-02-04 |
Evelo Biosciences, Inc. |
Inducing immune effects using bacteria of the genus bifidobacterium
|
|
EP4045062A1
(en)
|
2019-10-14 |
2022-08-24 |
Astrazeneca AB |
Modulators of pnpla3 expression
|
|
EP4086275A4
(en)
*
|
2019-12-31 |
2024-04-17 |
Xiamen University |
Multimerization delivery system for intracellular delivery of molecule
|
|
JP7459298B2
(ja)
|
2020-01-06 |
2024-04-01 |
シーサン・セラピューティクス |
細胞透過性核酸複合体を有効成分として含有する黄斑変性の予防又は治療用組成物
|
|
CR20220485A
(es)
|
2020-02-28 |
2022-11-10 |
Ionis Pharmaceuticals Inc |
Compuestos y métodos para modular smn2
|
|
CN115485385A
(zh)
|
2020-03-04 |
2022-12-16 |
瑞泽恩制药公司 |
用于使肿瘤细胞对免疫疗法敏感的方法和组合物
|
|
TW202146011A
(zh)
|
2020-03-05 |
2021-12-16 |
美商詹森藥物公司 |
治療b型肝炎病毒感染之組合療法
|
|
TW202202153A
(zh)
|
2020-03-26 |
2022-01-16 |
美商艾羅海德製藥公司 |
用於抑制ＰＮＰＬＡ３表現之ＲＮＡｉ劑、其醫藥組成物及使用方法
|
|
AU2021260934A1
(en)
|
2020-04-21 |
2022-11-24 |
Flagship Pioneering, Inc. |
Bifunctional molecules and methods of using thereof
|
|
US20230285357A1
(en)
|
2020-05-27 |
2023-09-14 |
The Regents Of The University Of California |
Compositions and methods for transdifferentiating cells
|
|
US20210403908A1
(en)
|
2020-06-22 |
2021-12-30 |
Janssen Pharmaceuticals, Inc. |
Compositions and methods for treatment of hepatitis d virus infection
|
|
IL301187A
(en)
|
2020-09-11 |
2023-05-01 |
Arrowhead Pharmaceuticals Inc |
RNAi agents for suppressing DUX4 expression, preparations containing them and uses thereof
|
|
AU2021342158A1
(en)
|
2020-09-11 |
2023-04-13 |
Arrowhead Pharmaceuticals, Inc. |
Lipid conjugates for the delivery of therapeutic agents
|
|
AU2021340710A1
(en)
|
2020-09-11 |
2023-04-06 |
Arrowhead Pharmaceuticals, Inc. |
Skeletal muscle delivery platforms and methods of use
|
|
WO2022056454A2
(en)
|
2020-09-14 |
2022-03-17 |
President And Fellows Of Harvard College |
Methods and compositions for treating hpv-positive cancers
|
|
IL301306A
(en)
|
2020-09-16 |
2023-05-01 |
Harvard College |
Methods of treating an individual that has failed an anti-pd-1/anti-pd-l1 therapy
|
|
EP4136092B1
(en)
|
2020-11-18 |
2024-07-31 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating angiotensinogen expression
|
|
TW202245809A
(zh)
|
2020-12-18 |
2022-12-01 |
美商詹森藥物公司 |
用於治療b型肝炎病毒感染之組合療法
|
|
WO2022152869A1
(en)
|
2021-01-15 |
2022-07-21 |
Janssen Sciences Ireland Unlimited Company |
Use of oligonucleotides for individuals with hepatic impairment
|
|
CN114767704B
(zh)
*
|
2021-01-21 |
2024-06-14 |
圣诺制药公司 |
一种能够靶向乙型肝炎病毒的药物构造及药物组合物
|
|
US12486502B2
(en)
|
2021-04-08 |
2025-12-02 |
Arrowhead Pharmaceuticals, Inc. |
RNAi agents for inhibiting expression of receptor for advanced glycation end-products, compositions thereof, and methods of use
|
|
CN117858949A
(zh)
|
2021-05-28 |
2024-04-09 |
箭头药业股份有限公司 |
用于抑制粘蛋白5AC(MUC5AC)的表达的RNAi试剂、其组合物及其使用方法
|
|
US11629349B2
(en)
|
2021-06-21 |
2023-04-18 |
Arrowhead Pharmaceuticals, Inc. |
RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of use
|
|
EP4367241A1
(en)
|
2021-07-09 |
2024-05-15 |
GlaxoSmithKline Intellectual Property (No.3) Limited |
Use of oligonucleotides for individuals with renal impairment
|
|
MX2024004011A
(es)
|
2021-10-01 |
2024-07-01 |
Adarx Pharmaceuticals Inc |
Composiciones moduladoras de precalicreína y métodos de uso de estas.
|
|
US20250108067A1
(en)
|
2021-11-09 |
2025-04-03 |
Viaqua Therapeutics Ltd. |
Compositions for aquaculturing
|
|
WO2023150181A1
(en)
|
2022-02-01 |
2023-08-10 |
President And Fellows Of Harvard College |
Methods and compositions for treating cancer
|
|
WO2023233290A1
(en)
|
2022-05-31 |
2023-12-07 |
Janssen Sciences Ireland Unlimited Company |
Rnai agents targeting pd-l1
|
|
EP4540390A2
(en)
|
2022-06-15 |
2025-04-23 |
Arrowhead Pharmaceuticals, Inc. |
Rnai agents for inhibiting expression of superoxide dismutase 1 (sod1), compositions thereof, and methods of use
|
|
US20240254485A1
(en)
|
2023-01-13 |
2024-08-01 |
Hemoshear Therapeutics, Inc. |
Sirnas targeting slc10a1 transcripts, compositions and uses thereof
|
|
WO2024197017A2
(en)
|
2023-03-21 |
2024-09-26 |
Arrowhead Pharmaceuticals, Inc. |
Rnai agents for inhibiting expression of complement factor b (cfb) pharmaceutical compositions thereof, and methods of use
|
|
WO2024220930A2
(en)
|
2023-04-20 |
2024-10-24 |
Adarx Pharmaceuticals, Inc. |
Mapt-modulating compositions and methods of use thereof
|
|
CN121398851A
(zh)
|
2023-05-12 |
2026-01-23 |
阿达尔克斯制药有限公司 |
Nmda配体缀合的化合物及其用途
|
|
IL324720A
(en)
|
2023-05-26 |
2026-01-01 |
Adarx Pharmaceuticals Inc |
SOD1 modulators and methods of using them
|
|
CN121712891A
(zh)
|
2023-06-20 |
2026-03-20 |
阿达尔克斯制药有限公司 |
Lrrk2调节组合物及其使用方法
|
|
WO2025038750A2
(en)
|
2023-08-14 |
2025-02-20 |
President And Fellows Of Harvard College |
Methods and compositions for treating cancer
|
|
IL326882A
(en)
|
2023-08-30 |
2026-04-01 |
Arrowhead Pharmaceuticals Inc |
RNAi agents for inhibiting expression of inhibitory subunit beta E (INHBE), their pharmaceutical compositions and methods of use
|
|
WO2025072748A2
(en)
|
2023-09-29 |
2025-04-03 |
Insitro, Inc. |
Compositions and methods for treating nonalcoholic fatty liver disease
|
|
WO2025090926A1
(en)
*
|
2023-10-26 |
2025-05-01 |
The Penn State Research Foundation |
Ultrasound-sensitive peptide particles with surface-bound gene editing tools for spatially resolved molecule delivery
|
|
WO2025137390A1
(en)
|
2023-12-20 |
2025-06-26 |
Arrowhead Pharmaceuticals, Inc. |
Rnai agents for inhibiting expression of activin receptor-like kinase 7 (alk7), compositions thereof, and methods of use
|
|
TW202546227A
(zh)
|
2024-01-18 |
2025-12-01 |
荷蘭商Ｐｒｏｑｒ治療上市公司Ｉｉ |
用於治療賀勒氏症候群（ｈｕｒｌｅｒ ｓｙｎｄｒｏｍｅ）的反義寡核苷酸
|
|
TW202602463A
(zh)
|
2024-03-22 |
2026-01-16 |
日商武田藥品工業股份有限公司 |
用於抑制細胞色素ｐ４５０家族７次家族ａ成員１（ｃｙｐ７ａ１）表現之組成物及方法
|
|
US12551569B2
(en)
|
2024-03-31 |
2026-02-17 |
Arrowhead Pharmaceuticals, Inc. |
RNAi agents for inhibiting expression of microtubule associated protein tau (MAPT), compositions thereof, and methods of use
|
|
GB202404661D0
(en)
|
2024-04-02 |
2024-05-15 |
Proqr Therapeutics Ii Bv |
Antisense oligoncleotides for the treatment of liver disease
|
|
WO2025224230A1
(en)
|
2024-04-25 |
2025-10-30 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of fatty liver disease
|
|
WO2025226980A2
(en)
|
2024-04-25 |
2025-10-30 |
Insitro, Inc. |
Compositions and methods for treating metabolic dysfunction-associated steatotic liver disease
|
|
WO2025242321A1
(en)
|
2024-05-24 |
2025-11-27 |
Glaxosmithkline Intellectual Property (No.3) Limited |
Novel use
|
|
US20260021195A1
(en)
|
2024-06-20 |
2026-01-22 |
Arrowhead Pharmaceuticals, Inc. |
Rnai agents for inhibiting expression of huntingtin (htt), compositions thereof, and methods of use
|
|
GB202410081D0
(en)
|
2024-07-11 |
2024-08-28 |
Proqr Therapeutics Ii Bv |
Antisense oligonucleotides for the treatment of cardiovascular disease
|
|
US20260015617A1
(en)
|
2024-07-12 |
2026-01-15 |
Novartis Ag |
DOUBLE STRANDED RNAi AGENTS, COMPOSITIONS AND METHODS OF USE
|
|
WO2026044017A2
(en)
|
2024-08-21 |
2026-02-26 |
Insitro, Inc. |
Compositions and methods for treating nonalcoholic fatty liver disease
|